Zealand Pharma Presents Phase 2 ZUPREME-1 Petrelintide Data at ADA 2026 Scientific Sessions

Phase 2 results from Zealand Pharma's ZUPREME-1 trial will land in front of the metabolic health scientific community on June 6–8, 2026, at the ADA Scientific Sessions in New Orleans, a disclosure that carries direct implications for peptide manufacturing capacity planning and CDMO pipeline positioning in the amylin analog space.

The ZUPREME-1 trial evaluated petrelintide, a once-weekly human amylin analog co-developed with Roche, across five dose levels against placebo in 493 participants at 32 sites across the United States, Poland, and Romania. The randomized, double-blind, placebo-controlled, Phase 2 dose-finding study ran a 16-week escalation period followed by a maintenance phase to week 42, with a primary endpoint of percentage change in body weight from baseline to week 28. Secondary endpoints included waist circumference, HbA1c, and high-sensitivity C-reactive protein. The dataset has been selected for the ADA Official Press Program, signaling its scientific weight within the field.

Three poster presentations accompany the ePoster Theater session. One poster addresses gastric emptying, a pharmacological differentiator relevant to formulation and patient tolerability profiling. A second presents preclinical data comparing petrelintide's effects on eating pattern and locomotor activity against semaglutide in a diet-induced obesity rat model, a comparison that process development teams at CDMOs will track as the amylin class moves toward potential late-stage manufacturing scale-up.

For plant heads and QA directors monitoring the peptide manufacturing landscape, the amylin analog class represents a structurally distinct production challenge from GLP-1 receptor agonists. Petrelintide's once-weekly subcutaneous format and amylin receptor mechanism require synthesis and formulation capabilities that differ from the GLP-1 platforms currently dominating capacity investment. Early Phase 2 efficacy and safety readouts from ZUPREME-1 will inform whether petrelintide advances toward Phase 3, the threshold at which commercial-scale peptide synthesis commitments typically begin.

The ADA symposium on amylin as a novel diabetes and obesity therapy, scheduled for June 5, 2026, provides additional regulatory and clinical context for the class, moderated by W. Timothy Garvey, MD, who also presents the ZUPREME-1 ePoster Theater session the following day.

The primary endpoint readout, percentage change in body weight at week 28, will be the figure manufacturing and regulatory stakeholders should track as a leading indicator of petrelintide's Phase 3 trajectory and the associated production capacity requirements it would generate.

Source: Zealand Pharma A/S via GlobeNewswire, May 27, 2026.